Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Releases Opinion On Developing New Rural Cooperative Medical Care System

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health, Ministry of Civil Affairs, Ministry of Finance, Ministry of Agriculture and State Administration of TCM jointly issued an opinion draft on consolidating and developinga new rural cooperative medical care system. This adds another important element to current healthcare reform documents. MOH officials point out that the healthcare reform plan's release and implementation do not mean the end of planning as many outstanding issues still remain. To support the reform, Ministry of Human Resources and Social Security disclosed that it will next release some seven documents, which include raising the efficiency of medical insurance fund utilization, resolving issues of non-native patients getting medical care, continuing migrant workers' medical insurance transfers, enhancing medical insurance service capability and strengthening overall project phasing. Some require alignment with other ministries such as the essential drugs department. (Click here for more - Chinese language)

You may also be interested in...



Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse

Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.

Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces

Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.

Global Pharma Guidance Tracker – November 2019

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

UsernamePublicRestriction

Register

SC072298

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel